FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Expanding Real-World Evidence Use in Device Regulation

[ Price : $8.95]

CDRH leaders describe efforts to expand the use of real-world evidence in a range of medical device regulatory activities.

FDA Enforcement Discretion for Some Hemp CBD Products

[ Price : $8.95]

FDA says it will exercise enforcement discretion and not enforce specific sections of the Federal Food, Drug, and Cosmetic Act as ...

Trump Plans New Tariffs on Pharmaceutical Industry

[ Price : $8.95]

President Trump prepares to impose sweeping new tariffs on certain pharmaceutical imports, targeting companies that have not agree...

New CBER Head Should Restore Rare Disease Clarity: Advocates

[ Price : $8.95]

A rare disease coalition calls on the Trump administration to appoint a new CBER director who understands rare disease drug develo...

Multiple Violations at LeeSar Outsourcing Facility

[ Price : $8.95]

An FDA untitled letter cautions the Fort Myers, FL-based LeeSar drug outsourcing facility about CGMP and other violations in its p...

Multiple Violations in Physitemp Instruments Inspection

[ Price : $8.95]

FDA warns Clifton, NJ-based Physitemp Instruments about Quality System, Medical Device Reporting, Unapproved Device, and Unique De...

Appeals Court Hears GLP-1 Compounding Testimony

[ Price : $8.95]

A Courthouse New Service report outlines the competing arguments made before a three-judge appeals court panel in a case involving...

FDA Seeks Faster IND-To-Approval Timelines, Expanded OTC Access

[ Price : $8.95]

FDA commissioner Marty Makary says the agency is prioritizing efforts to accelerate drug development timelines beginning at the IN...

FDA Extends Review Timeline for Orca Bios Cell Therapy Orca-T

[ Price : $8.95]

FDA extends by three months its review of an Orca Bio BLA for its experimental cell therapy Orca-T, indicated for treating a range...

Xbrane Plans Resubmission of Lucentis Biosimilar by June

[ Price : $8.95]

Xbrane Biopharma says it plans to resubmit a BLA before June for ranibizumab, a biosimilar copy of Genentechs Lucentis, which is i...